Drug intelligence / Profile preview

ICA06

Development stage: Preclinical
Lead developer: iCamuno Biotherapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic

Overview

ICA06 is an induced pluripotent stem cell (iPSC)-based cell therapy being developed by iCamuno Biotherapeutics for the treatment of various ophthalmological conditions. As part of iCamuno's pipeline of universal, off-the-shelf cell products, ICA06 leverages the company's iPSC platform to generate specialized ocular cells intended to restore or support visual function. The program is currently in the preclinical stage of development, focusing on establishing safety and efficacy in eye disease models.

Beyond the preview

Go deeper on ICA06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICA06.

Explore the full profile